Aussie Try To Lower Drug Costs Ends Up Raising Most, Report Says
This article was originally published in PharmAsia News
Australia's attempt to lower the cost and obtain a better drug value under its health-insurance plan appears to have backfired, according to a report
You may also be interested in...
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.
HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe.